Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria
Sharon Onguti, Mary M. Czech, Elizabeth Robilotti, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 7, pp. 1303-1312
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

The past, present, and future of antibiotics
Michael A. Cook, Gerard D. Wright
Science Translational Medicine (2022) Vol. 14, Iss. 657
Closed Access | Times Cited: 361
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
Ghazala Muteeb, Md Tabish Rehman, Moyad Shahwan, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1615-1615
Open Access | Times Cited: 284
Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics
Bismillah Mubeen, Aunza Nayab Ansar, Rabia Rasool, et al.
Antibiotics (2021) Vol. 10, Iss. 12, pp. 1473-1473
Open Access | Times Cited: 157
Intrinsic antimicrobial resistance: Molecular biomaterials to combat microbial biofilms and bacterial persisters
Swagatam Barman, Leman Buzoglu Kurnaz, Ryan Leighton, et al.
Biomaterials (2024) Vol. 311, pp. 122690-122690
Closed Access | Times Cited: 20
Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales
Rémy A. Bonnin, Cécile Emeraud, Agnès B. Jousset, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 8, pp. 1156.e1-1156.e5
Open Access | Times Cited: 59
Antibiotic-Resistant ESKAPE Pathogens and COVID-19: The Pandemic beyond the Pandemic
Alessia Catalano, Domenico Iacopetta, Jessica Ceramella, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1843-1843
Open Access | Times Cited: 26
Novel Antimicrobial Agents for Gram-Negative Pathogens
Marios Karvouniaris, Maria Panagiota Almyroudi, Mohd H. Abdul‐Aziz, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 761-761
Open Access | Times Cited: 23
In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
Mark G. Wise, James A. Karlowsky, Meredith Hackel, et al.
Microbial Drug Resistance (2023) Vol. 29, Iss. 8, pp. 360-370
Open Access | Times Cited: 20
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion
Nicola Coppola, Alberto Enrico Maraolo, Lorenzo Onorato, et al.
Antibiotics (2022) Vol. 11, Iss. 9, pp. 1263-1263
Open Access | Times Cited: 24
Genomics of Acinetobacter baumannii iron uptake
Irene Artuso, Harsh Poddar, Benjamin A. Evans, et al.
Microbial Genomics (2023) Vol. 9, Iss. 8
Open Access | Times Cited: 15
Navigating Antibiotic Resistance in Gram‐Negative Bacteria: Current Challenges and Emerging Therapeutic Strategies
Reshma Kumari, Ishu Saraogi
ChemPhysChem (2025)
Closed Access
Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
Hao Lin, Zhu Chen, Shuang Liu, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Biosynthetic Investigations of Ulbactins Unveil Two Novel Thiazolinyl Imine Reductases Crucial for the Generation of Siderophore Activity
Yuan Gu, Zong-Jie Wang, Huimei Wang, et al.
Journal of Agricultural and Food Chemistry (2025)
Closed Access
Cytoplasmic Delivery of an Antibiotic, Trimethoprim, with a Simple Bidentate Catechol Analog as a Siderophore Mimetic
Do Young Kim, Suyeon Yeom, Jimin Park, et al.
ACS Infectious Diseases (2023) Vol. 9, Iss. 3, pp. 554-566
Closed Access | Times Cited: 12
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol
Gabriele Bianco, Matteo Boattini, Monica Cricca, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 12, pp. 14132-14153
Open Access | Times Cited: 4
Innovative perspectives on the discovery of small molecule antibiotics
Silvia T. Cardona, A. S. M. Zisanur Rahman, Julieta Novomisky Nechcoff
npj Antimicrobials and Resistance (2025) Vol. 3, Iss. 1
Open Access
Systematic review and meta-analysis on the prevalence of extended-spectrum β-lactamases-producing Acinetobacter baumannii in Iran: Evaluation of TEM, PER, SHV, CTX-M, VEB and GES
Hamid Sadeghi, Mehdi Bakht, Susan Khanjani, et al.
Microbial Pathogenesis (2025), pp. 107554-107554
Closed Access
Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives
Pingxian Liu, Yunhan Jiang, Ling Jiao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 13860-13873
Closed Access | Times Cited: 9
Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa
Scott W. Mueller, Kyle C. Molina, Brittany Blass, et al.
Journal of Burn Care & Research (2024) Vol. 45, Iss. 3, pp. 808-810
Open Access | Times Cited: 3
The Molecular Mouse System: A New Useful Tool for Guiding Antimicrobial Therapy in Critically Ill Septic Patients
Carola Mauri, Alessandra Consonni, Elena Briozzo, et al.
Antibiotics (2024) Vol. 13, Iss. 6, pp. 517-517
Open Access | Times Cited: 3
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study
Daniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 9, pp. 1929-1948
Open Access | Times Cited: 3
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii
Wentao Ni, Yifan Wang, Xinqian Ma, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2022) Vol. 41, Iss. 12, pp. 1451-1457
Closed Access | Times Cited: 14
Assessment of cefiderocol disk diffusion versus broth microdilution results when tested against Acinetobacter baumannii complex clinical isolates
Yanling Liu, Li Ding, Renru Han, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 8
In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
Lucia Mališová, Iveta Vrbova, Katarína Pomorská, et al.
Microbial Drug Resistance (2023) Vol. 29, Iss. 10, pp. 485-491
Closed Access | Times Cited: 7
Discovery of YFJ-36: Design, Synthesis, and Antibacterial Activities of Catechol-Conjugated β-Lactams against Gram-Negative Bacteria
Fangjun Liu, Qunhuan Kou, Hongyuan Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6705-6725
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top